For ET patients (Supplementary Fig. S1), only the presence of a JAK2 mutation was associated with increased risk (HR: 2.6, 95% CI: 1.2–5.5, p = 0.012) in univariate analysis. This evidence concerns the gene JAK2 and essential thrombocythemia.